While the cell efficacy multiplier platform technology has the potential to transform the field of cell therapy by improving efficacy, reducing the cost of care, and reducing patient wait time, our focus has been primarily on advancing our cancer immunotherapy medicine.
Our most advanced product, TZ 101, is currently in the phase 3 readiness stage and initially aims to enhance the efficacy and safety of hematopoietic stem cell transplantation (HSCT). HSCT is a potentially curative therapy and is commonly used as a first-line treatment for various hematologic malignancies. However, it is often reserved as a last resort due to its potentially life-threatening side effects. Complications associated with HSCT, such as infections, graft-versus-host disease (GVHD), and stem cell engraftment failure, contribute significantly to post-HSCT mortality rates, limiting its application to end-stage patients. Our goal with TZ 101 is to improve the safety and efficacy of HSCT to the point where it can be used as a front-line potentially curative therapy for cancer patients. Additionally, we aim to make HSCT safer and more effective, potentially offering a cure for patients with autoimmune diseases by rebooting their immune systems through HSCT.
Our FucoTIL products are scheduled to enter clinical trials next year. The goal for FucoTILs is to enable cures for metastatic cancer patients with solid tumors by harnessing and empowering their own immune system to effectively eradicate cancer in a safe and efficacious manner.